F. Barlesi, J. Mazieres, J. P. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet Lond Engl, vol.387, issue.16, pp.4-4, 2016.

T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, vol.361, pp.947-57, 2009.

M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, vol.362, pp.2380-2388, 2010.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-285, 2012.

L. V. Sequist, J. Yang, N. Yamamoto, K. O'byrne, V. Hirsh et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, vol.31, pp.3327-3361, 2013.

A. B. Cortot and P. A. Jänne, Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas, Eur Respir Rev, vol.23, pp.356-66, 2014.

W. Zhou, D. Ercan, L. Chen, C. H. Yun, D. Li et al., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, vol.462, pp.1070-1074, 2009.

P. A. Jänne, J. C. Yang, D. W. Kim, D. Planchard, Y. Ohe et al., AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, vol.372, pp.1689-99, 2015.

J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, vol.316, pp.1039-1082, 2007.

J. Bean, C. Brennan, J. Y. Shih, G. Riely, A. Viale et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

U. Sci, , vol.104, pp.20932-20939, 2007.

M. E. Arcila, G. R. Oxnard, K. Nafa, G. J. Riely, S. B. Solomon et al., Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay, Clin Cancer Res, vol.17, pp.1169-80, 2011.

L. V. Sequist, B. A. Waltman, D. Santagata, D. Digumarthy, S. Turke et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, vol.3, 2011.

H. A. Yu, M. E. Arcila, N. Rekhtman, C. S. Sima, M. F. Zakowski et al., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, vol.19, pp.2240-2247, 2013.

R. Noro, M. Seike, F. Zou, C. Soeno, K. Matsuda et al., MET FISHpositive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation, BMC Cancer, vol.15, p.31, 2015.

H. U. Schildhaus, A. M. Schultheis, J. Rüschoff, E. Binot, M. Bruse et al., MET amplification status in therapy-naïve adeno-and squamous cell carcinomas of the lung, Clin Cancer Res, vol.21, pp.907-922, 2015.

S. Park, J. Koh, D. W. Kim, M. Kim, B. Keam et al., MET amplification, protein expression, and mutations in pulmonary adenocarcinoma, Lung Cancer Amst Neth, vol.90, pp.381-388, 2015.

L. Y. Gou, A. N. Li, J. J. Yang, X. C. Zhang, J. Su et al., The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer, Oncotarget, vol.7, pp.51311-51319, 2016.

J. F. Gainor, M. J. Niederst, J. K. Lennerz, I. Dagogo-jack, S. Stevens et al., Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification, J Thorac Oncol, vol.11, pp.83-85, 2016.

M. Bahcall, T. Sim, C. P. Paweletz, J. D. Patel, R. S. Alden et al., Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer, Cancer Discov, vol.6, pp.1335-1341, 2016.

A. Tanaka, N. Sueoka-aragane, T. Nakamura, Y. Takeda, M. Mitsuoka et al., Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients, Lung Cancer Amst Neth, vol.75, pp.89-94, 2012.

F. Cappuzzo, A. Marchetti, M. Skokan, E. Rossi, S. Gajapathy et al., Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients, J Clin Oncol, vol.27, pp.1667-74, 2009.

F. Cappuzzo, P. A. Jänne, M. Skokan, G. Finocchiaro, E. Rossi et al., MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients, Ann Oncol, vol.20, pp.298-304, 2009.

M. G. Kris, B. E. Johnson, L. D. Berry, D. J. Kwiatkowski, A. J. Iafrate et al., Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, vol.311, 1998.

D. Casadevall, J. Gimeno, S. Clavé, Á. Taus, L. Pijuan et al., MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC), Oncotarget, vol.6, pp.16215-16241, 2015.

I. Watermann, B. Schmitt, F. Stellmacher, J. Müller, R. Gaber et al., Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?, Diagn Pathol, vol.10, p.130, 2015.

M. Beau-faller, A. M. Ruppert, A. C. Voegeli, A. Neuville, N. Meyer et al., MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort, J Thorac Oncol, vol.3, pp.331-340, 2008.

D. R. Camidge, S. Ou, G. Shapiro, G. A. Otterson, L. C. Villaruz et al., Efficacy and safety of crizotinib in patients with advanced www.impactjournals.com/oncotarget c-MET-amplified non-small cell lung cancer (NSCLC), J Clin Oncol, vol.32, p.5, 2014.

S. A. Noonan, L. Berry, X. Lu, D. Gao, A. E. Barón et al., Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis, J Thorac Oncol, vol.11, pp.1293-304, 2016.

K. Kryeziu, C. Pirker, B. Englinger, S. Van-schoonhoven, M. Spitzwieser et al., Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells, Oncotarget, vol.7, p.27379, 2016.

J. H. Tong, S. F. Yeung, A. W. Chan, L. Y. Chung, S. L. Chau et al., MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis, Clin Cancer Res, vol.22, pp.3048-56, 2016.

J. Lee, S. H. Ou, J. M. Lee, H. C. Kim, M. Hong et al., Gastrointestinal malignancies harbor actionable MET exon 14 deletions, Oncotarget, vol.6, pp.28211-28233, 2015.

G. R. Oxnard, M. E. Arcila, C. S. Sima, G. J. Riely, J. Chmielecki et al., Acquired resistance to EGFR tyrosine kinase inhibitors in EGFRmutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation, Clin Cancer Res, vol.17, pp.1616-1638, 2011.

J. M. Sun, M. J. Ahn, Y. L. Choi, J. S. Ahn, and K. Park, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors, Lung Cancer Amst Neth, vol.82, pp.294-302, 2013.

A. Dimou, L. Non, Y. K. Chae, W. J. Tester, and K. N. Syrigos, MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis, PloS One, vol.9, 2014.

B. Guo, H. Cen, X. Tan, W. Liu, and Q. Ke, Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures, PloS One, vol.9, 2014.

A. B. Turke, K. Zejnullahu, Y. L. Wu, Y. Song, D. Dias-santagata et al., Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC, Cancer Cell, vol.17, pp.77-88, 2010.

Y. L. Wu, D. W. Kim, E. Felip, L. Zhang, X. Liu et al., Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMETpositive (cMET+) non-small cell lung cancer (NSCLC), J Clin Oncol, vol.34, 2016.

A. Hata, N. Katakami, H. Yoshioka, J. Takeshita, K. Tanaka et al., Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations, Cancer, vol.119, pp.4325-4357, 2013.